Genovate Biotechnology Co (ROCO:4130) Other Financing: NT$-11.1 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4130 Genovate Biotechnology Co Ltd ROCO:4130
73 GF Score
Price NT$27.55
GF Value NT$22.20
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Genovate Biotechnology Co Other Financing?

Genovate Biotechnology Co ROCO:4130 +2.61% 73 Other Financing is NT$-11.1 Mil as of Dec. 2025. GuruFocus rates ROCO:4130 with a GF Score™ of 73/100 and a GF Value™ of NT$22.20 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Genovate Biotechnology Co's Other Financing for the three months ended in Dec. 2025 was NT$0.0 Mil.

Genovate Biotechnology Co's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-11.1 Mil.

Genovate Biotechnology Co Other Financing Historical Data

* Premium members only.

The historical data trend for Genovate Biotechnology Co's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genovate Biotechnology Co Other Financing Chart

Genovate Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.06 0.16 -0.01 0.05

Genovate Biotechnology Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.30 0.00 0.05 -11.15 0.00
ROCO:4130
73GF Score
Genovate Biotechnology Co Ltd ROCO:4130
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genovate Biotechnology Co Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-11.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of NT$-11.1 Mil mean?
Genovate Biotechnology Co (ROCO:4130) has a Other Financing of NT$-11.1 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Genovate Biotechnology Co and its competitors.
Is Genovate Biotechnology Co's Other Financing too high?
Genovate Biotechnology Co's current Other Financing is NT$-11.1 Mil. Overall, Genovate Biotechnology Co has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genovate Biotechnology Co's Other Financing compare to VRTX and REGN?
Genovate Biotechnology Co's Other Financing of NT$-11.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Genovate Biotechnology Co and its competitors. Genovate Biotechnology Co's current Other Financing is NT$-11.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovate Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Genovate Biotechnology Co (ROCO:4130) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$22.20, compared to a current price of NT$27.55 — trading 24.1% above its estimated fair value. The current Other Financing is NT$-11.1 Mil. Genovate Biotechnology Co's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Genovate Biotechnology Co (ROCO:4130), the current Other Financing is NT$-11.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genovate Biotechnology Co (ROCO:4130) Overvalued in 2026?

Based on GuruFocus' analysis, Genovate Biotechnology Co stock appears to be overvalued. The current stock price of NT$27.55 is trading 24.1% above its estimated GF Value™ of NT$22.20. GuruFocus considers Genovate Biotechnology Co to be Modestly Overvalued.

Key valuation signals for ROCO:4130:

  • Other Financing: NT$-11.1 Mil
  • GF Value™: NT$22.20 vs. price of NT$27.55 (24.1% above fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4130 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genovate Biotechnology Co Business Description

Address No.1, First Industrial Road, Hsin-Chu Expanded Park, Hukou Township, Guangdong Province, Hsin-Chu county, Hsin-Chu, TWN, 303036
Genovate Biotechnology Co Ltd develops, produces, manufactures, and sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc. The company is also engaged in the sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases etc.
73GF Score

Get the complete analysis for ROCO:4130

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$27.55
Price
NT$22.20
GF Value